



CÔNG TY CỔ PHẦN  
DƯỢC PHẨM CPC1 HÀ NỘI  
HA NOI CPC1  
PHARMACEUTICAL JSC

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM  
Độc lập – Tự do – Hạnh phúc  
SOCIALIST REPUBLIC OF VIETNAM  
Independence – Freedom – Happiness

Số/No. 301 /2026/CV-CPC1HN

Hà Nội, ngày 20 tháng 7 năm 2026  
Hanoi, July 20, 2026

**CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH**  
**INFORMATION DISCLOSURE FINANCIAL STATEMENT**

Kính gửi/To.

- Ủy ban chứng khoán nhà nước/ *The State Securities Commission*;
- Sở Giao dịch Chứng khoán Hà Nội/ *Hanoi Stock Exchange* ;

Thực hiện quy định tại khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, Công ty Cổ phần Dược phẩm CPC1 Hà Nội thực hiện công bố thông tin Báo cáo tài chính (BCTC) Quý II năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

*Pursuant to Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the securities market, Ha Noi CPC1 Pharmaceutical Joint Stock Company hereby discloses its Second Quarter 2026 Financial Statements to the Hanoi Stock Exchange as follows:*

**1. Tên tổ chức/ Name of organization:**

Mã chứng khoán/ *Stock code*: DTP

Địa chỉ/ *Address*: Cụm Công nghiệp Hà Bình Phương, xã Thường Tín, thành phố Hà Nội/ *Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi city*

Điện thoại liên hệ/ *Phone*: 0243.3765503 Website: <https://cpc1hn.com.vn/>

**2. Nội dung thông tin công bố/ Disclosed Information:**

Báo cáo tài chính Quý II năm 2026/ *Second Quarter 2026 Financial Statements*

☒ BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc)/ *Separate Financial Statements (For listed organizations without subsidiaries and with subordinate accounting units under the same accounting entity)*;

☐ BCTC hợp nhất (TCNY có công ty con)/ *Consolidated Financial Statements (For listed organizations with subsidiaries)*;

☐ BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kế toán riêng)/ *Combined Financial Statements (For listed organizations with subordinate accounting units that maintain independent accounting records)*.



- Các trường hợp thuộc diện phải giải trình nguyên nhân/ *Cases subject to explanation of causes:*

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC đã được soát xét/kiểm toán 2025)/ *The audit firm issues an opinion other than an unqualified opinion on the financial statements (for the reviewed/audited financial statements of the year 2025):*

☐ Có/Yes

☐ Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

☐ Có/Yes

☐ Không/No

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2025)/ *Profit after tax in the reporting period differs by 5% or more before and after audit/review, or changes from loss to profit or vice versa (for audited financial statements of the year 2025):*

☐ Có/Yes

☒ Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

☐ Có/Yes

☐ Không/No

+ Lợi nhuận sau thuế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước/ *Corporate income tax profit at the financial result of the report changes by 10% or more compared to the same period of the previous year:*

☒ Có/Yes

☐ Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

☒ Có/Yes

☐ Không/No

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại/ *The profit after tax in the reporting period is a loss, switching from profit in the same period of the previous year to a loss in this period or vice versa:*

☐ Có/Yes

☒ Không/No

Văn bản giải trình trong trường hợp tích có/ *Written explanation required if selected "Yes":*

☐ Có/Yes

☐ Không/No

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 20/07/2026 tại đường dẫn: <https://cpc1hn.com.vn/co-dong/bao-cai-tai-chinh>.

*This information has been disclosed on the Company's website on July 20, 2026 at the following link: <https://cpc1hn.com.vn/co-dong/bao-cai-tai-chinh>.*

Trân trọng/ Sincerely,

**Tài liệu đính kèm/ Attachment:**

- BCTC Quý II năm 2026/ *Second Quarter 2026 Financial Statements;*
- Văn bản giải trình/ *Explanatory Statement.*

**ĐẠI DIỆN TỔ CHỨC**  
**Người Ủy quyền công bố thông tin**  
**HA NOI CPC1 PHARMACEUTICAL**  
**JOINT STOCK COMPANY**  
**Authorized Information Disclose Representative**



**Tạ Thị Hải Huyền**



**HANOI CPC1 PHARMACEUTICAL JOINT STOCK COMPANY**

**FINANCIAL STATEMENTS**

**For the Second Quarter Ended June 30, 2026**



# **HA NOI CPC1 PHARMACEUTICAL JSC**

Ha Binh Phuong Industrial Cluster , Thuong Tin Commune, Ha Noi City, Viet Nam

---

## **TABLE OF CONTENTS**

| <b>CONTENTS</b>                                                    | <b>Pages</b> |
|--------------------------------------------------------------------|--------------|
| <b>FINANCIAL STATEMENTS FOR SECOND QUARTER ENDED JUNE 30, 2026</b> |              |
| Statement of Financial Position                                    | 02 - 03      |
| Income Statement                                                   | 04           |
| Cash Flow Statement                                                | 05-06        |
| Notes to the Financial Statements                                  | 07 - 25      |

**STATEMENT OF FINANCIAL POSITION**

As at 30 June 2026

Unit: VND

**FORM B 01a-DN**

| ASSETS                                               | Code       | 30/06/2026               | 01/01/2026               |
|------------------------------------------------------|------------|--------------------------|--------------------------|
| <b>A - CURRENT ASSETS</b>                            | <b>100</b> | <b>967,641,114,633</b>   | <b>929,287,491,503</b>   |
| <b>I. Cash and cash equivalents</b>                  | <b>110</b> | <b>112,275,406,292</b>   | <b>122,066,528,932</b>   |
| 1. Cash                                              | 111        | 37,275,406,292           | 37,566,528,932           |
| 2. Cash equivalents                                  | 112        | 75,000,000,000           | 84,500,000,000           |
| <b>II. Short-term financial investments</b>          | <b>120</b> | -                        | -                        |
| <b>III. Short-term receivables</b>                   | <b>130</b> | <b>387,027,639,075</b>   | <b>379,016,875,148</b>   |
| 1. Short-term trade receivables                      | 131        | 281,373,245,759          | 308,409,634,515          |
| 2. Short-term prepayments to suppliers               | 132        | 87,469,104,992           | 62,934,511,008           |
| 5. Other short-term receivables                      | 135        | 19,463,159,689           | 8,765,341,523            |
| 6. Provision for doubtful short-term receivables (*) | 136        | (1,277,871,365)          | (1,092,611,898)          |
| <b>IV. Inventories</b>                               | <b>140</b> | <b>462,492,250,799</b>   | <b>424,400,430,272</b>   |
| 1. Inventories                                       | 141        | 465,018,343,490          | 427,064,873,865          |
| 2. Provision for devaluation of inventories (*)      | 142        | (2,526,092,691)          | (2,664,443,593)          |
| <b>VI. Other current assets</b>                      | <b>160</b> | <b>5,845,818,467</b>     | <b>3,803,657,151</b>     |
| 1. Short-term prepaid expenses                       | 161        | 5,475,030,290            | 3,803,563,728            |
| 2. Deductible VAT                                    | 162        | 370,773,463              | -                        |
| 3. Tax and other receivables from the State          | 163        | 14,714                   | 93,423                   |
| <b>B - NON-CURRENT ASSETS</b>                        | <b>200</b> | <b>681,286,252,064</b>   | <b>651,558,813,793</b>   |
| <b>I. Long-term receivables</b>                      | <b>210</b> | <b>3,362,562,552</b>     | <b>3,112,075,667</b>     |
| 1. Other long-term receivables                       | 215        | 3,362,562,552            | 3,112,075,667            |
| <b>II. Fixed assets</b>                              | <b>220</b> | <b>537,352,708,229</b>   | <b>418,493,023,562</b>   |
| 1. Tangible fixed assets                             | 221        | 362,095,908,615          | 387,935,857,428          |
| - Cost                                               | 222        | 782,450,689,997          | 768,559,352,057          |
| - Accumulated depreciation (*)                       | 223        | (420,354,781,382)        | (380,623,494,629)        |
| 2. Intangible fixed assets                           | 227        | 175,256,799,614          | 30,557,166,134           |
| - Cost                                               | 228        | 183,340,740,867          | 38,299,446,867           |
| - Accumulated amortization (*)                       | 229        | (8,083,941,253)          | (7,742,280,733)          |
| <b>V. Long-term work in progress</b>                 | <b>250</b> | <b>60,791,918,127</b>    | <b>145,785,399,824</b>   |
| 1. Construction in progress                          | 252        | 60,791,918,127           | 145,785,399,824          |
| <b>VII. Other non-current assets</b>                 | <b>270</b> | <b>79,779,063,156</b>    | <b>84,168,314,740</b>    |
| 1. Long-term prepaid expenses                        | 271        | 79,779,063,156           | 84,168,314,740           |
| <b>TOTAL ASSETS (270 = 100 + 200)</b>                | <b>280</b> | <b>1,648,927,366,697</b> | <b>1,580,846,305,296</b> |

**STATEMENT OF FINANCIAL POSITION (Continued)**

As at 30 June 2026

Unit: VND

**FORM B 01a-DN**

| <b>EQUITY AND LIABILITIES</b>                                        | <b>Code</b> | <b>30/06/2026</b>        | <b>01/01/2026</b>        |
|----------------------------------------------------------------------|-------------|--------------------------|--------------------------|
| <b>C - LIABILITIES</b>                                               | <b>300</b>  | <b>399,458,005,573</b>   | <b>380,651,424,489</b>   |
| <b>I. Current liabilities</b>                                        | <b>310</b>  | <b>328,870,049,550</b>   | <b>346,853,239,489</b>   |
| 1. Short-term trade payables                                         | 311         | 80,986,382,739           | 51,786,056,897           |
| 2. Short-term advances from customers                                | 312         | 78,626,217,444           | 50,670,248,247           |
| 3. Dividends and profits payable                                     | 313         | 32,458,047,200           | -                        |
| 4. Taxes and amounts payable to the State                            | 314         | 7,244,769,615            | 30,029,793,095           |
| 5. Payables to employees                                             | 315         | 31,559,940,175           | 118,490,874,214          |
| 6. Short-term accrued expenses                                       | 316         | -                        | 70,976,849               |
| 10. Other short-term payables                                        | 320         | 16,766,043,908           | 17,325,184,595           |
| 11. Short-term borrowings and finance lease liabilities              | 321         | 57,676,024,747           | 47,706,529,100           |
| 13. Bonus and welfare fund                                           | 323         | 23,552,623,722           | 30,773,576,492           |
| <b>II. Non-current liabilities</b>                                   | <b>330</b>  | <b>70,587,956,023</b>    | <b>33,798,185,000</b>    |
| 1. Other long-term payables                                          | 338         | 291,730,000              | 521,500,000              |
| 2. Long-term borrowings and finance lease liabilities                | 339         | 70,296,226,023           | 33,276,685,000           |
| <b>D - OWNER'S EQUITY</b>                                            | <b>400</b>  | <b>1,249,469,361,124</b> | <b>1,200,194,880,807</b> |
| 1. Owner's contributed capital                                       | 411         | 405,725,590,000          | 324,580,840,000          |
| - Ordinary shares with voting rights                                 | 411a        | 405,725,590,000          | 324,580,840,000          |
| - Preferred shares                                                   | 411b        | -                        | -                        |
| 2. Share premium                                                     | 412         | 9,442,260,000            | 9,442,260,000            |
| 8. Investment and development fund                                   | 418         | 94,353,394,407           | 94,353,394,407           |
| 10. Undistributed after-tax profit                                   | 420         | 739,948,116,717          | 771,818,386,400          |
| - Accumulated undistributed profit up to the end of the prior period | 420a        | 626,358,058,746          | 488,376,533,082          |
| - Undistributed profit for the current period                        | 420b        | 113,590,057,971          | 283,441,853,318          |
| <b>TOTAL EQUITY AND LIABILITIES (440 = 300 + 400)</b>                | <b>440</b>  | <b>1,648,927,366,697</b> | <b>1,580,846,305,296</b> |

*Ha Noi, 20 July 2026*

**Preparer**



**Nguyen Thi Xuan Hoan**

**Chief Accountant**



**Dang Thi Thu Thuy**

**Chairman of the Board of Directors**



**Le Nam Thang**

**INCOME STATEMENT**  
For the three-month period ended 30 June 2026

Unit: VND

**FORM B 02a- DN**

| ITEMS                                                                          | Codes     | Three-month<br>period ended 30<br>June 2026 | Three-month<br>period ended 30<br>June 2025 | Cumulative from<br>January 1, 2026 to<br>June 30, 2026 | Cumulative from<br>January 1, 2025 to<br>June 30, 2025 |
|--------------------------------------------------------------------------------|-----------|---------------------------------------------|---------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| 1. Revenue from sale of goods and rendering of services                        | 01        | 464,922,138,297                             | 395,622,443,976                             | 879,614,339,288                                        | 725,851,016,538                                        |
| 2. Revenue deductions                                                          | 02        | 2,077,082,215                               | 1,721,644,458                               | 4,349,584,152                                          | 2,432,353,330                                          |
| <b>3. Net revenue from sale of goods and rendering of services</b>             | <b>10</b> | <b>462,845,056,082</b>                      | <b>393,900,799,518</b>                      | <b>875,264,755,136</b>                                 | <b>723,418,663,208</b>                                 |
| 4. Cost of goods sold                                                          | 11        | 239,626,388,943                             | 182,023,862,630                             | 458,785,934,020                                        | 339,811,110,237                                        |
| <b>5. Gross profit from sale of goods and rendering of services (20=10-11)</b> | <b>20</b> | <b>223,218,667,139</b>                      | <b>211,876,936,888</b>                      | <b>416,478,821,116</b>                                 | <b>383,607,552,971</b>                                 |
| 6. Financial income                                                            | 22        | 955,086,513                                 | 261,114,117                                 | 2,351,316,547                                          | 604,305,640                                            |
| 8. Financial expenses                                                          | 23        | 1,353,848,481                               | 1,802,626,396                               | 2,682,583,957                                          | 2,957,280,419                                          |
| <i>In which: Interest expense</i>                                              | 24        | 1,124,528,946                               | 1,802,626,396                               | 2,244,270,926                                          | 2,132,292,098                                          |
| 8. Selling expenses                                                            | 25        | 147,450,999,799                             | 108,926,873,256                             | 267,283,558,051                                        | 200,557,660,680                                        |
| 9. General and administration expenses                                         | 26        | 12,367,709,453                              | 10,910,845,836                              | 22,121,345,836                                         | 18,998,601,650                                         |
| <b>10. Net profit from operating activities {30= 20+ 21+22-(23+25+26)}</b>     | <b>30</b> | <b>63,001,195,919</b>                       | <b>90,497,705,517</b>                       | <b>126,742,649,819</b>                                 | <b>161,698,315,862</b>                                 |
| 11. Other income                                                               | 31        | 621,660,584                                 | 43,095,609                                  | 731,121,949                                            | 242,006,213                                            |
| 12. Other expenses                                                             | 32        | 222,549,703                                 | 4,731,694,131                               | 281,710,613                                            | 21,354,485,929                                         |
| <b>13. Other profit (40= 31-32)</b>                                            | <b>40</b> | <b>399,110,881</b>                          | <b>- 4,688,598,522</b>                      | <b>449,411,336</b>                                     | <b>- 21,112,479,716</b>                                |
| <b>14. Total accounting profit before tax (50 = 30 + 40)</b>                   | <b>50</b> | <b>63,400,306,800</b>                       | <b>85,809,106,995</b>                       | <b>127,192,061,155</b>                                 | <b>140,585,836,146</b>                                 |
| 15. Current corporate income tax expense                                       | 51        | 5,173,457,084                               | 9,716,269,075                               | 13,602,003,184                                         | 17,521,164,267                                         |
| <b>17. Profit after corporate income tax (60 = 50 - 51 - 52)</b>               | <b>60</b> | <b>58,226,849,716</b>                       | <b>76,092,837,920</b>                       | <b>113,590,057,971</b>                                 | <b>123,064,671,879</b>                                 |

*Ha Noi, 20 July 2026*

**Preparer**



**Nguyen Thi Xuan Hoan**

**Chief Accountant**



**Dang Thi Thu Thuy**

**Chairman of the Board of Directors**



**Le Nam Thang**

**CASH FLOW STATEMENT**  
(Indirect Method)  
For the three-month period ended 30 June 2026

Unit: VND

FORM B 03-DN

| ITEMS                                                                                    | Codes | Cumulative from the<br>beginning of the year to the<br>end of this quarter (Current<br>Period) | Cumulative from the<br>beginning of the year to the<br>end of this quarter (Previous<br>Period) |
|------------------------------------------------------------------------------------------|-------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| <b>I. CASH FLOWS FROM OPERATING ACTIVITIES</b>                                           |       |                                                                                                |                                                                                                 |
| 1. <i>Profit before tax</i>                                                              | 01    | 127,192,061,155                                                                                | 140,585,836,146                                                                                 |
| 2. <i>Adjustments for</i>                                                                |       |                                                                                                |                                                                                                 |
| - Depreciation and amortization of fixed assets and investment properties                | 02    | 40,072,947,273                                                                                 | 36,057,041,142                                                                                  |
| - Provisions                                                                             | 03    | 46,908,565                                                                                     | (147,587,490)                                                                                   |
| - Gains/losses from investment activities                                                | 05    | (1,486,521,898)                                                                                | (384,851,266)                                                                                   |
| - Interest expenses                                                                      | 06    | 2,244,270,926                                                                                  | 2,132,292,098                                                                                   |
| - Other adjustments                                                                      | 07    | -                                                                                              | 15,832,201,461                                                                                  |
| 3. <i>Operating profit before changes in working capital</i>                             | 08    | 168,115,786,534                                                                                | 194,596,284,386                                                                                 |
| - Increase/decrease in receivable                                                        | 09    | (8,446,510,279)                                                                                | (47,627,596,072)                                                                                |
| - Increase/decrease in inventories                                                       | 10    | (37,953,469,625)                                                                               | 20,848,403,060                                                                                  |
| - Increase/decrease in payable (excluding interest payable/corporate income tax payable) | 11    | (6,679,266,964)                                                                                | (49,598,642,823)                                                                                |
| - Increase/decrease in prepaid expense                                                   | 12    | 2,717,785,022                                                                                  | (1,183,972,997)                                                                                 |
| - Interest paid                                                                          | 14    | (3,123,253,906)                                                                                | (2,192,055,848)                                                                                 |
| - Corporate income tax paid                                                              | 15    | (32,801,524,563)                                                                               | (34,719,912,164)                                                                                |
| - Other income from operating activities                                                 | 16    | -                                                                                              | -                                                                                               |
| - Other payments on operating activities                                                 | 17    | (71,580,575,397)                                                                               | (2,069,928,849)                                                                                 |
| <i>Net Cash Flows from Operating Activities</i>                                          | 20    | 10,248,970,822                                                                                 | 78,052,578,693                                                                                  |
| <b>II. CASH FLOWS FROM INVESTING ACTIVITIES</b>                                          |       |                                                                                                | -                                                                                               |
| 1. Purchase or construction of fixed assets and long-term assets                         | 21    | (68,403,571,951)                                                                               | (57,463,210,829)                                                                                |
| 5. Interest and dividend received                                                        | 27    | 1,486,521,898                                                                                  | 349,851,266                                                                                     |
| <i>Net Cash Flows from Investing Activities</i>                                          | 30    | (66,917,050,053)                                                                               | (52,078,359,563)                                                                                |
| <b>III. CASH FLOWS FROM FINANCING ACTIVITIES</b>                                         |       | -                                                                                              | -                                                                                               |
| 1. Proceeds from borrowings                                                              | 33    | 99,147,466,038                                                                                 | 38,476,672,774                                                                                  |
| 2. Repayment of principal                                                                | 34    | (52,264,735,942)                                                                               | (43,502,925,012)                                                                                |
| <i>Net Cash Flows from Financing Activities</i>                                          | 40    | 46,882,730,096                                                                                 | (5,026,252,238)                                                                                 |
| <b>Net cash flows in the period (50=20+30+40)</b>                                        | 50    | (9,785,349,135)                                                                                | 20,947,966,892                                                                                  |

**CASH FLOW STATEMENT(Continued)**

*(Indirect Method)*

For the three-month period ended 30 June 2026

Unit: VND

| ITEMS                                                          | Codes | Cumulative from the<br>beginning of the year to the<br>end of this quarter (Current<br>Period) | Cumulative from the<br>beginning of the year to the<br>end of this quarter (Previous<br>Period) |
|----------------------------------------------------------------|-------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Cash and cash equivalents at the beginning of the period       | 60    | 122,066,528,932                                                                                | 39,923,026,642                                                                                  |
| Effects of changes in foreign exchange rates                   | 61    | (5,773,505)                                                                                    | 7,109,190                                                                                       |
| Cash and cash equivalents at the end of the period (70=50+60+6 | 70    | 112,275,406,292                                                                                | 60,878,102,724                                                                                  |

*Ha Noi, 20 July 2026*

**Preparer**



**Nguyen Thi Xuan Hoan**

**Chief Accountant**



**Dang Thi Thu Thuy**

**Chairman of the Board of Directors**



**Le Nam Thang**

**NOTES TO FINANCIAL STATEMENTS**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**I. GENERAL INFORMATION**

**Structure of ownership**

CPC1 Hanoi Pharmaceutical Joint Stock Company was established and operates under Business Registration Certificate No. 0104089394 issued by Hanoi Department of Planning and Investment for the first time on 5 August 2009, registered for the 18th change on 24 June 2026.

The Company's head office is located at Ha Binh Phuong Industrial Cluster, Van Binh Commune, Thuong Tin District, Hanoi City, Vietnam.

Charter capital: VND 405,725,590,000 (In words: Four hundred five billion, seven hundred twenty-five million, five hundred ninety thousand Vietnamese dong only ./.

**Business lines**

The Company's business activities include:

- Warehousing and storage of goods; Wholesale of medical machinery and equipment;
- Urban and suburban passenger road transport;
- Road freight transport; Trade promotion and introduction services;
- Manufacturing of plastic packaging; wooden packaging; production of corrugated paper, cardboard, and paper-based packaging;
- Advertising services; Manufacturing of medical, dental, orthopedic, and rehabilitation equipment and instruments;
- Production of cosmetics, soap, detergents, polishes, and sanitary preparations;
- Production of non-alcoholic beverages and mineral water; Leasing of machinery, equipment, and other tangible goods;
- Real estate business; Wholesale of pharmaceuticals and medical instruments; Wholesale of perfumes, cosmetics, and sanitary products;
- Pharmaceutical retail business; Passenger transport by provincial and inter-provincial coaches; Leasing of chauffeur-driven vehicles for passenger transport, including tours, sightseeing, and other purposes;
- Business consulting and assistance services related to planning, organizing, operations, and management information; Consulting services for business establishment and corporate management support;
- Market research and public opinion polling;
- Retail sale of medical instruments, cosmetics, and sanitary items in specialized stores;
- Retail sale of eyeglasses and optical products;
- Production of functional foods, micronutrient-fortified foods, nutritional products, healthcare foods, dietary supplements, and other processed foods (excluding those banned by law);
- Wholesale of functional foods, micronutrient-fortified foods, nutritional products, healthcare foods, dietary supplements, and other processed foods (excluding those banned by law);
- Retail sale of functional foods, micronutrient-fortified foods, nutritional products, healthcare foods, dietary supplements, and other processed foods (excluding those banned by law);
- Wholesale of vaccines and medical biological products; Export and import of pharmaceuticals; Import of medical equipment; Wholesale of medicinal herbs, traditional medicine, and herbal medicines; Wholesale of disinfectant products for household and healthcare use; Wholesale of food ingredients and additives, and animal feed;
- Entrusted import services;
- Provision of pharmaceutical storage services; Commercial representation; Import and export of goods within the Company's business scope.

**Normal Operating Cycle**

The company's normal production and business cycle is completed within a period not exceeding 12 months.

**HANOI CPC1 PHARMACEUTICAL JSC**

Ha Binh Phuong Industrial Cluster , Van Binh Commune, Thuong  
Tin District, Ha Noi City, Viet Nam

**FINANCIAL STATEMENTS**

For the accounting period  
From April 1, 2026 to June 30, 2026

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**Corporate Structure**

The company has dependent accounting branches as follows:

| <b>The Company has the following affiliated units:</b>                           | <b>Address</b>                                                                                                                     |
|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| CPC1 Hanoi Pharmaceutical Joint Stock Company - Hanoi Branch                     | DX Lot, Southwest Linh Dam Urban Area, Hoang Liet Ward, Hanoi City                                                                 |
| CPC1 Hanoi Pharmaceutical Joint Stock Company - Da Nang Branch                   | No. 170 Nguyen Dinh Tuu, Lien Chieu ward, Da Nang city                                                                             |
| CPC1 Hanoi Pharmaceutical Joint Stock Company - Ho Chi Minh City Branch          | No. 26-28, Han Mac Tu Street, Phu Tho Hoa Ward, Ho Chi Minh City                                                                   |
| Representative Office of CPC1 Hanoi Pharmaceutical Joint Stock Company           | No. 81 Thong Nhat Street, Phu Tho Hoa Ward, Ho Chi Minh City                                                                       |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Thanh Hoa   | MB2125, Lots N27+N28, Le Hien Tong Street, Hac Thanh Ward, Thanh Hoa Province                                                      |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Hai Phong   | Lot HA.S01, Vinhomes Marina Urban Area, An Bien Ward, Hai Phong City                                                               |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Nghe An     | Apartment No. 109, 12-storey Building in the New Urban Area, West V.I. Lenin Boulevard, Hamlet 19, Vinh Phu Ward, Nghe An Province |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Khanh Hoa   | Lot No. 4, Road No. 93, Thai Hung Urban Area (Package 05, My Gia Urban Area), Nam Nha Trang Ward, Khanh Hoa Province               |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Can Tho     | Plot No. 2158, Map Sheet No. 1, Road No. 3, Lot 11B Residential Area, South Can Tho Urban Area, Hung Phu Ward, Can Tho City        |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Dak Lak     | Plot Nos. 2263, 2264, Map Sheet No. 19, Buon Ma Thuot Ward, Dak Lak Province                                                       |
| Business Location - CPC1 Hanoi Pharmaceutical Joint Stock Company in Thai Nguyen | Land Plot No. 1525, Map Sheet No. 75, Thang Long Urban Area, Group 40, Phan Dinh Phung Ward, Thai Nguyen Province                  |

**II. BASIC OF PREPARATION OF FINANCIAL STATEMENTS AND ACCOUNTING PERIOD**

The accompanying financial statements for the accounting period are presented in Vietnamese Dong (VND), prepared on a historical cost basis, and in accordance with Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and relevant legal regulations on the preparation and presentation of financial statements for the accounting period.

The accompanying financial statements for the accounting period are not intended to present the financial position, business results, and cash flows in accordance with generally accepted accounting principles and practices in countries other than Vietnam.

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**Accounting period**

The Company's financial year begins on January 1 and ends on December 31 of the calendar year.

**III. APPLICABLE ACCOUNTING STANDARDS AND REGULATIONS**

**Accounting regime applied**

The Company applies the Vietnamese Enterprise Accounting Regime issued under Circular No. 99/2025/TT-BTC dated December 27, 2025 by the Ministry of Finance

**Statement of Compliance with Accounting Standards and Accounting Regime**

The Company has applied the Vietnamese Accounting Standards and all relevant guidance documents issued by the competent authorities. The financial statements for the reporting period have been prepared and presented in full compliance with the provisions of each applicable standard, the relevant implementing circulars, and the prevailing enterprise accounting regime.

**Applied accounting form**

The Company applies a computerized accounting system using the Fast Business accounting software.

**IV. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The preparation of financial statements for each accounting period complies with the Vietnamese Accounting Standards, the Enterprise Accounting Regime, and other relevant legal regulations.

**Cash and cash equivalents**

Cash and cash equivalents consist of cash on hand, non-term bank deposits, short-term investments (not exceeding 3 months) with high liquidity, easily convertible to cash, and minimal risk associated with value fluctuations.

**Receivables**

Receivables are amounts that can be recovered from customers or other entities. Receivables are presented at book value minus allowances for doubtful debts (if any).

Allowances for doubtful debts are established for receivables that are past due for six months or more, or receivables from parties who may have difficulty in payment due to liquidation, bankruptcy, or similar difficulties. The provision is based on the aging of overdue receivables or the estimated loss that may occur, as follows:

- For overdue receivables:
  - 30% of the value for receivables overdue from 6 months to less than 1 year
  - 50% of the value for receivables overdue from 1 year to less than 2 years
  - 70% of the value for receivables overdue from 2 years to less than 3 years
  - 100% of the value for receivables that are overdue for 3 years or more
- For receivables not yet overdue but deemed difficult to collect: provisions are based on estimated losses.

Changes in the balance of allowances for doubtful debts need to be recognized as an expense in the corporate management expenses on the date of the financial report.

**Inventories**

Inventory is determined based on the lower of cost and net realizable value. The cost of inventory includes direct material costs, direct labor costs, and overhead costs incurred to acquire inventory at its

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

current location and condition. The cost of inventory is determined using the weighted average method and is accounted for using the periodic inventory system. The net realizable value is determined by estimated selling prices minus estimated costs to complete the product along with marketing, selling, and distribution costs.

The company establishes provisions for inventory impairment in accordance with current accounting regulations. Accordingly, the company is permitted to set up provisions for obsolete, damaged, or inferior quality inventory, and in cases where the cost of inventory exceeds the net realizable value at the date of the financial report.

**Tangible fixed assets and depreciation**

Tangible fixed assets are presented at cost less accumulated depreciation.

The cost of tangible fixed assets includes the purchase price and all other directly attributable costs related to placing the asset in a usable condition.

For fixed assets with a revaluation adjustment, depreciation is calculated using the new cost minus the accumulated depreciation, divided by the remaining useful life.

Any subsequent costs incurred after initial recognition of the tangible fixed asset are added to the asset's carrying amount if they are reasonably expected to increase future economic benefits from the use of the asset. Costs that do not meet this condition are recognized as expenses in the period incurred.

Tangible fixed assets are depreciated using the straight-line method based on their estimated useful lives. The depreciation periods are as follows:

|                                                      | <u>Estimated useful life (year)</u> |
|------------------------------------------------------|-------------------------------------|
| Buildings and structures                             | 05 - 45                             |
| Machinery and equipment                              | 04 - 15                             |
| Transportation and transmission                      | 06 - 10                             |
| Perennial plants, working animals and farm livestock | 08                                  |
| Other tangible fixed assets                          | 02 - 12                             |

**Intangible fixed assets and amortization**

***Land use rights***

Land use rights are presented at cost less accumulated depreciation, representing the value of the right to use 30,306.3 square meters of leased land in Ha Binh Phuong Industrial Cluster, Thuong Tin Commune, Hanoi City for 45 years by the Company. Land use rights are allocated using the straight-line method over the term of the land lease.

Land use rights located in Thai Nguyen Province, Ca Mau Province, and Ho Chi Minh City

***Accounting Software***

Accounting software is initially recognized at cost, including the purchase price and directly related costs incurred to put the asset into use as intended. Accounting software is depreciated using the straight-line method over a period of 3 years

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**Construction in Progress**

Assets under construction for production, leasing, management, or any other purpose are recognized at cost. This cost includes service charges and interest expenses related to appropriate accounting policies of the Company. Depreciation for these assets is calculated similarly to other assets, starting from when the assets are ready for use.

**Prepaid Expenses**

Prepaid expenses are actual costs incurred but related to the results of business operations over multiple accounting periods. These include significant repair costs for fixed assets, one-time-use tools and equipment with substantial value, and the tools and equipment themselves participating in business activities over a financial year, considered capable of providing future economic benefits to the Company. These costs are capitalized as prepaid expenses and allocated to the Income Statement using the straight-line method according to current accounting regulations.

**Payables**

The principle of determining amounts payable to vendors is based on contracts, warehouse receipts, and recorded based on invoices from the seller.

Prepayments to vendors are recorded based on payment vouchers, bank documents, and economic contracts.

Detailed tracking of accounts payable to suppliers is carried out, and at the end of the month, a reconciliation statement of accounts payable is sent to suppliers for confirmation.

**Accrued expenses**

Accrued expenses represent estimated costs for business operations in the accounting period but have not yet been incurred due to the lack of formal settlement with the supplier for goods or services provided.

**Owner's equity**

Owner's equity is recorded based on the actual contributed capital of the owner.

Capital surplus is recorded based on the difference between the increase resulting from the issuance of shares above par value and the difference between the increase and decrease compared to the purchase price when selling treasury shares.

The principle of recognizing undistributed profits is the profit (or loss) from the Company's business operations minus (-) adjustments due to the retroactive application of changes in accounting policies and adjustments to material errors of previous years.

The principle of establishing reserves, funds from after-tax profits is based on the resolution of the Annual General Meeting of Shareholders

**Revenue and Other Income Recognition**

**Revenue from sales**

Revenue from sales is recognized when all five (5) of the following conditions are met simultaneously

- Most of the risks and rewards incidental to ownership of the product or goods have been transferred to the buyer;

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

- The Company no longer holds the right to manage the goods as the owner of the goods or the right to control the goods;
- The revenue can be measured reliably
- The Company has obtained or will receive economic benefits from the sales transaction;
- The costs related to the sales transaction can be reliably identified;

***Revenue from services***

Revenue from service provision transactions is recognized when the outcome of the transaction is reliably determinable. In cases where service provision transactions span multiple periods, revenue is recognized in the period based on the results of the completed portion of the work as of the date of the Balance Sheet for that period. The outcome of the service provision transaction is determined when all four (4) of the following conditions are met:

- Revenue is reliably determinable;
- Economic benefits have been received or will be received from the service provision transaction
- The completed portion of the work as of the date of the Balance Sheet is determined
- The costs incurred for the transaction and the costs to complete the service provision transaction are identifiable

In the case of service provision spanning multiple accounting periods, revenue recognition for the service in each period is done using the percentage-of-completion method.

***Financial income***

Revenue arising from interest and other financial income is recognized when the following two (2) conditions are satisfied:

- There is a probability of economic benefits from the transaction;
- Revenue is reliably determinable.

***Foreign currencies***

Transactions denominated in foreign currency are translated at the exchange rates prevailing at the transaction dates. The balances of items denominated in foreign currencies at the end of the accounting period are translated at the rates prevailing on that date

The exchange rate differences arising during the period from foreign currency transactions are recognized in the Income Statement. Exchange rate differences arising from the revaluation of items denominated in foreign currencies at the reporting date, after offsetting increases and decreases, are recognized in financial income or financial expenses.

***Borrowing costs***

Borrowing costs are recognized as expenses in the period they are incurred unless capitalized in accordance with the Accounting Standard "Borrowing Costs". Accordingly, borrowing costs directly attributable to the acquisition, construction, or production of assets that require a relatively long period to complete for use or sale are added to the carrying amount of the assets until the assets are ready for use or sale. Income arising from the temporary investment of borrowed funds is deducted from the carrying amount of the related assets. For borrowings specifically obtained to finance the construction of fixed assets, investment properties, interest expenses are capitalized even if the construction period is less than 12 months.

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**Taxation**

***Value added tax***

The company pays value added tax using the deduction method, with the following tax rates:

| <b>Business activities</b>               | <b>Tax rate</b> |
|------------------------------------------|-----------------|
| - Export of pharmaceuticals              | 0%              |
| - Sale of pharmaceuticals                | 5%              |
| - Activities of selling functional foods | 8%              |

***Corporate income tax***

- Current Corporate Income Tax Expense

Current corporate income tax expense is determined based on the taxable income for the year and the applicable corporate income tax rate in the current financial year.

- Tax Incentive Policy

The Company is recognized as a science and technology enterprise under Certificate No. 44/DNKHCN, initially issued on July 19, 2018, by the Hanoi Department of Science and Technology. Accordingly, the Company is entitled to corporate income tax exemptions and reductions in accordance with Article 12 of Decree No. 13/2019/ND-CP dated February 1, 2019, of the Government on science and technology enterprises, provided that revenue from products derived from scientific and technological results accounts for at least 30% of the Company's total revenue. As a result, the Company is exempt from corporate income tax for 4 years and is entitled to a 50% reduction of the payable tax amount for the subsequent 9 years starting from 2018.

- Current Corporate Income Tax Rate

Corporate income tax is calculated at the applicable rate of 20% on taxable income, effective as of the end of the reporting period.

Other types of taxes are applied according to the current tax laws in Vietnam

**Earnings per share**

Earnings per share for common stock are calculated by dividing the profit or loss attributable to common shareholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share take into account the potential dilution from other securities that could convert into common stock, such as convertible bonds and stock options.

**Related parties**

Parties are considered related if one party has the ability to control or significantly influence the other party in making financial and operating policy decisions.

Individuals, directly or indirectly through one or more intermediaries, who have control over the Company or are under common control with the Company

Affiliated parties and individuals who directly or indirectly hold voting rights in the Company and have significant influence over the Company

Key management personnel such as the General Director, members of the Company, close family members of these individuals or affiliated parties, or companies affiliated with these individuals are also considered related parties

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**V. ADDITIONAL INFORMATION FOR ITEMS PRESENTED ON THE BALANCE SHEET**

**1. CASH AND CASH EQUIVALENTS**

|                      | <u>30/06/2026</u>             | <u>01/01/2026</u>             |
|----------------------|-------------------------------|-------------------------------|
| Cash on hand         | 548,170,069                   | 459,378,460                   |
| Cash in banks        | 36,727,236,223                | 37,107,150,472                |
| Cash equivalents (*) | 75,000,000,000                | 84,500,000,000                |
| <b>Total</b>         | <u><u>112,275,406,292</u></u> | <u><u>244,133,057,864</u></u> |

(\*) As at 30 June 2026, cash equivalents represent a 1-month term deposit amounting to VND 75,000,000,000

**2. HELD-TO-MATURITY INVESTMENTS**

|               | <u>30/06/2026</u> | <u>01/01/2026</u> |
|---------------|-------------------|-------------------|
| Term deposits | -                 | -                 |
| <b>Cộng</b>   | <u><u>-</u></u>   | <u><u>-</u></u>   |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**3. SHORT-TERM TRADE RECEIVABLES**

|                                                                           | <b>30/06/2026</b>      | <b>01/01/2026</b>      |
|---------------------------------------------------------------------------|------------------------|------------------------|
| <b>Related parties</b>                                                    | <b>29,703,623,584</b>  | <b>23,630,256,423</b>  |
| CPC1 Central Pharmaceutical Joint Stock Company - Ho Chi Minh City Branch | 14,829,234             | 6,145,997              |
| CPC1 Central Pharmaceutical Joint Stock Company - Nghe An Branch          | 1,253,858              | -                      |
| CPC1 Central Pharmaceutical Joint Stock Company                           | -                      | 43,548,000             |
| VNP Pharmaceutical Company Limited                                        | 4,765,398,737          | 8,425,896,820          |
| Tan Thinh Pharmaceutical Company Limited                                  | 6,711,747,171          | 8,118,056,262          |
| Upharma Joint Stock Company                                               | 18,210,394,584         | 7,036,609,344          |
| <b>Other parties</b>                                                      | <b>251,669,622,175</b> | <b>284,779,378,092</b> |
| Thuan Phat Manufacturing and Development Investment Company Limited       | 16,483,248,569         | 15,060,097,971         |
| Thanh Nhan Hospital                                                       | 1,707,210,000          | 1,723,926,500          |
| Binh Minh Pharmaceutical Company Limited                                  | 3,542,201,380          | 3,542,201,380          |
| Other trade receivables                                                   | 229,936,962,226        | 264,453,152,241        |
| <b>Total</b>                                                              | <b>281,373,245,759</b> | <b>308,409,634,515</b> |

**4. SHORT-TERM ADVANCES TO SUPPLIERS**

|                                                                | <b>30/06/2026</b>     | <b>01/01/2026</b>     |
|----------------------------------------------------------------|-----------------------|-----------------------|
| <b>Other parties</b>                                           | <b>87,469,104,992</b> | <b>62,934,511,008</b> |
| Hoang Lan Construction Joint Stock Company                     | -                     | 1,059,000,000         |
| Hop Luc Construction Joint Stock Company                       | 2,493,760,659         | 17,920,426,402        |
| NTK Fire Protection Consulting and Engineering Company Limited | 3,936,600,000         | -                     |
| OURLEAD PTE. LTD                                               | 23,873,550,698        | 19,004,400,000        |
| Other suppliers                                                | 57,165,193,635        | 24,950,684,606        |
| <b>Total</b>                                                   | <b>87,469,104,992</b> | <b>62,934,511,008</b> |

**5. OTHER RECEIVABLES**

|                                                                | <b>30/06/2026</b>     | <b>01/01/2026</b>    |
|----------------------------------------------------------------|-----------------------|----------------------|
| <b>Other short-term receivables</b>                            | <b>50,000,000</b>     | <b>50,000,000</b>    |
| <b>Related parties</b>                                         | <b>50,000,000</b>     | <b>50,000,000</b>    |
| CPC1 Central Pharmaceutical Joint Stock Company                | 50,000,000            | 50,000,000           |
| <b>Other parties</b>                                           | <b>19,413,159,689</b> | <b>8,715,341,523</b> |
| Advances to employees                                          | 18,662,674,094        | 7,909,474,381        |
| Deposits and collateral                                        | 445,905,682           | 478,734,314          |
| Advances for entrusted import goods                            | -                     | 302,784,064          |
| Other short-term receivables                                   | 304,579,913           | 24,348,764           |
| <b>Total</b>                                                   | <b>19,463,159,689</b> | <b>8,765,341,523</b> |
| <b>Other long-term receivables</b>                             | <b>30/06/2026</b>     | <b>01/01/2026</b>    |
| <b>Related parties</b>                                         | <b>-</b>              | <b>-</b>             |
| <b>Other parties</b>                                           | <b>3,362,562,552</b>  | <b>3,112,075,667</b> |
| Asia Commercial Joint Stock Bank                               | 1,732,540,149         | 1,732,540,149        |
| Binh Tien Consumer Goods Manufacturing Company Limited (BITTS) | 600,000,000           | 600,000,000          |
| Deposits and collateral                                        | 1,030,022,403         | 779,535,518          |
| <b>Total</b>                                                   | <b>3,362,562,552</b>  | <b>3,112,075,667</b> |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**6. INVENTORIES**

|                                | 30/06/2026             |                      | 01/01/2026             |                      |
|--------------------------------|------------------------|----------------------|------------------------|----------------------|
|                                | Giá gốc                | Dự Phòng             | Giá gốc                | Dự Phòng             |
| Goods in transit               | -                      | -                    | 12,476,947,242         | -                    |
| Raw materials                  | 161,047,408,127        | 538,514,457          | 131,525,864,774        | 696,809,127          |
| Tools and supplies             | -                      | -                    | 14,093,380             | -                    |
| Work in progress               | -                      | -                    | 8,998,336,504          | -                    |
| Merchandise and finished goods | -                      | 1,987,578,234        | 274,049,631,965        | 1,967,634,466        |
|                                | <b>161,047,408,127</b> | <b>2,526,092,691</b> | <b>427,064,873,865</b> | <b>2,664,443,593</b> |

**7. CONSTRUCTION IN PROGRESS**

|                                        | 30/06/2026            | 01/01/2026             |
|----------------------------------------|-----------------------|------------------------|
| Purchase of fixed assets               | 129,722,220           | 130,768,167,000        |
| Basic construction                     | 60,466,908,777        | 14,821,945,694         |
| Upgrade and renovation of fixed assets | 195,287,130           | 195,287,130            |
| <b>Total</b>                           | <b>60,791,918,127</b> | <b>145,785,399,824</b> |

**HANOI CPC1 PHARMACEUTICAL JSC**

Ha Binh Phuong Industrial Cluster , Van Binh Commune, Thuong Tin District, Ha Noi City, Viet Nam

**FINANCIAL STATEMENTS**

 For the accounting period  
From April 1, 2026 to June 30, 2026

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements

**8. TANGIBLE FIXED ASSETS**

Unit: VND

|                                      | Buildings and structures | Machinery and equipment | Means of transportation and transmission | Management equipment and tools | Other fixed assets    | Total                  |
|--------------------------------------|--------------------------|-------------------------|------------------------------------------|--------------------------------|-----------------------|------------------------|
| <b>Historical cost</b>               |                          |                         |                                          |                                |                       |                        |
| Balance as at 01/01/2026             | 158,956,780,559          | 543,520,458,832         | 32,446,130,166                           | 870,499,091                    | 32,765,483,409        | 768,559,352,057        |
| - Purchases                          | -                        | 12,163,909,342          | 1,701,729,091                            | -                              | 640,660,369           | 14,506,298,802         |
| - Repair and upgrade                 | 1,491,901,679            | -                       | -                                        | -                              | -                     | 1,491,901,679          |
| - Other decreases                    | -                        | (1,496,000,000)         | -                                        | -                              | (610,862,541)         | (2,106,862,541)        |
| <b>Balance as at 30/06/2026</b>      | <b>160,448,682,238</b>   | <b>554,188,368,174</b>  | <b>34,147,859,257</b>                    | <b>870,499,091</b>             | <b>32,795,281,237</b> | <b>782,450,689,997</b> |
| <b>Accumulated depreciation</b>      |                          |                         |                                          |                                |                       |                        |
| Balance as at 01/01/2026             | 38,029,661,383           | 300,525,627,005         | 22,755,890,114                           | 655,764,664                    | 18,656,551,463        | 380,623,494,629        |
| - Depreciation charge for the period | 3,590,445,474            | 32,042,010,707          | 1,987,631,923                            | 155,254,164                    | 2,643,966,644         | 40,419,308,912         |
| - Other decreases                    | -                        | (77,159,618)            | -                                        | -                              | (610,862,541)         | (688,022,159)          |
| <b>Balance as at 30/06/2026</b>      | <b>41,620,106,857</b>    | <b>332,490,478,094</b>  | <b>24,743,522,037</b>                    | <b>811,018,828</b>             | <b>20,689,655,566</b> | <b>420,354,781,382</b> |
| <b>Net book value</b>                |                          |                         |                                          |                                |                       |                        |
| As at 01/01/2026                     | 120,927,119,176          | 242,994,831,827         | 9,690,240,052                            | 214,734,427                    | 14,108,931,946        | 387,935,857,428        |
| <b>As at 30/06/2026</b>              | <b>118,828,575,381</b>   | <b>221,697,890,080</b>  | <b>9,404,337,220</b>                     | <b>59,480,263</b>              | <b>12,105,625,671</b> | <b>362,095,908,615</b> |



**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**11. BORROWINGS AND FINANCE LEASE LIABILITIES**

|                                                                                               | <b>30/06/2026</b>     | <b>01/01/2026</b>     |
|-----------------------------------------------------------------------------------------------|-----------------------|-----------------------|
| <b>Short-term borrowings</b>                                                                  |                       |                       |
| <i>Short-term borrowings from related parties</i>                                             | -                     | -                     |
| <i>Short-term VND bank borrowings</i>                                                         | <b>16,503,338,370</b> | <b>15,382,005,532</b> |
| Vietnam Joint Stock Commercial Bank for Industry and Trade - Thai Binh Branch                 | 14,184,140,218        | 5,185,112,996         |
| Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch              | 2,319,198,152         | 10,196,892,536        |
| <i>Short-term bank borrowings in foreign currency</i>                                         | <b>33,372,686,377</b> | <b>21,874,523,568</b> |
| Asia Commercial Joint Stock Bank (ACB) - Timescity Transaction Office                         | 29,753,077,120        | 18,544,930,064        |
| Vietnam Joint Stock Commercial Bank for Industry and Trade - Thai Binh Branch                 | 3,619,609,257         | 1,094,645,500         |
| Joint Stock Commercial Bank for Foreign Trade of Vietnam - Nam Thang Long Branch              | -                     | 2,234,948,004         |
| <i>Long-term borrowings due for repayment</i>                                                 | <b>7,800,000,000</b>  | <b>10,450,000,000</b> |
| Asia Commercial Joint Stock Bank (ACB) - Timescity Transaction Office                         | -                     | 2,750,000,000         |
| Joint Stock Commercial Bank for Investment and Development of Vietnam (BIDV) - My Dinh Branch | 7,800,000,000         | 7,700,000,000         |
| <b>Total</b>                                                                                  | <b>57,676,024,747</b> | <b>47,706,529,100</b> |
| <b>Long-term borrowings</b>                                                                   |                       |                       |
| Asia Commercial Joint Stock Bank (ACB) - Timescity Transaction Office                         | -                     | -                     |
| Joint Stock Commercial Bank for Investment and Development of Vietnam (BIDV) - My Dinh Branch | 16,100,000,000        | 20,000,000,000        |
| Vietnam Joint Stock Commercial Bank for Industry and Trade - Thai Binh Branch                 | 54,196,226,023        | 13,276,685,000        |
| <b>Total</b>                                                                                  | <b>70,296,226,023</b> | <b>33,276,685,000</b> |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**12. SHORT-TERM TRADE PAYABLES**

|                                                                 | 30/06/2026            | 01/01/2026            |
|-----------------------------------------------------------------|-----------------------|-----------------------|
| <i>Related parties</i>                                          | -                     | -                     |
| <i>Other parties</i>                                            | 78,626,217,444        | 50,670,248,247        |
| Nguyen Gia Pharmaceutical and Cosmetics Trading Company Limited | 834,120,000           | -                     |
| Hoang Son Pharmaceutical Trading Joint Stock Company            | 227,850,000           | 113,925,000           |
| Green Vietnam Pharmaceutical Trading Company Limited            | 5,022,622,075         | -                     |
| Other advances from customers                                   | 72,541,625,369        | 50,556,323,247        |
| <b>Total</b>                                                    | <b>78,626,217,444</b> | <b>50,670,248,247</b> |

**13. SHORT-TERM ADVANCES FROM CUSTOMERS**

|                                                                 | 30/06/2026            | 01/01/2026            |
|-----------------------------------------------------------------|-----------------------|-----------------------|
| <i>Related parties</i>                                          | -                     | -                     |
| <i>Other parties</i>                                            | 78,626,217,444        | 50,670,248,247        |
| Nguyen Gia Pharmaceutical and Cosmetics Trading Company Limited | 834,120,000           | -                     |
| Hoang Son Pharmaceutical Trading Joint Stock Company            | 227,850,000           | 113,925,000           |
| Green Vietnam Pharmaceutical Trading Company Limited            | 5,022,622,075         | -                     |
| Other advances from customers                                   | 72,541,625,369        | 50,556,323,247        |
| <b>Total</b>                                                    | <b>78,626,217,444</b> | <b>50,670,248,247</b> |

**14. DIVIDENDS AND PROFIT PAYABLE**

|                              | 30/06/2026            | 01/01/2026 |
|------------------------------|-----------------------|------------|
| Dividends and profit payable | 32,458,047,200        | -          |
| <b>Cộng</b>                  | <b>32,458,047,200</b> | <b>-</b>   |

**15. TAXES AND OTHER RECEIVABLES/ PAYABLES TO THE STATE BUDGET**

|                                  | 30/06/2026           |               | 01/01/2026            |               |
|----------------------------------|----------------------|---------------|-----------------------|---------------|
|                                  | Payable              | Receivable    | Payable               | Receivable    |
| Value added tax                  | 876,822,858          | -             | 3,694,321,693         | -             |
| Import VAT                       | -                    | -             | -                     | -             |
| Import and export duties         | -                    | 14,714        | -                     | 93,423        |
| Corporate income tax             | 4,069,003,184        | -             | 23,268,524,563        | -             |
| Personal income tax              | 2,298,943,573        | -             | 3,066,946,839         | -             |
| Land rental                      | -                    | -             | -                     | -             |
| Other taxes                      | -                    | -             | -                     | -             |
| Fees, charges and other payables | -                    | -             | -                     | -             |
| <b>Total</b>                     | <b>7,244,769,615</b> | <b>14,714</b> | <b>30,029,793,095</b> | <b>93,423</b> |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**16. SHORT-TERM ACCRUED EXPENSES**

|                                                        | 30/06/2026 | 01/01/2026        |
|--------------------------------------------------------|------------|-------------------|
| <i>Payables to related parties</i>                     | -          | -                 |
| <i>Payables to other organizations and individuals</i> | -          | 70,976,849        |
| Other short-term accrued expenses                      | -          | 70,976,849        |
| <b>Total</b>                                           | <b>-</b>   | <b>70,976,849</b> |

**17. OTHER PAYABLES**

| <i>Other short-term payables</i>      | 30/06/2026            | 01/01/2026            |
|---------------------------------------|-----------------------|-----------------------|
| Trade union fees and insurance        | 3,609,648,705         | 1,955,344,968         |
| Advances received for entrusted goods | -                     | 300,000,000           |
| Other short-term payables             | 13,156,395,203        | 15,069,839,627        |
| <b>Total</b>                          | <b>16,766,043,908</b> | <b>17,325,184,595</b> |

  

| <i>Other long-term payables</i>  | 30/06/2026         | 01/01/2026         |
|----------------------------------|--------------------|--------------------|
| Deposits and collateral received | 291,730,000        | 521,500,000        |
| <b>Total</b>                     | <b>291,730,000</b> | <b>521,500,000</b> |

**HANOI CPC1 PHARMACEUTICAL JSC**

Ha Binh Phuong Industrial Cluster , Van Binh Commune, Thuong Tin District, Ha Noi City, Viet Nam

**FINANCIAL STATEMENTS**

 For the accounting period  
From April 1, 2026 to June 30, 2026

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements

**18. OWNER'S EQUITY**

Unit: VND

**a. Reconciliation of movements in owners' equity**

|                                            | Owners' contributed capital | Share premium        | Development investment fund | Undistributed earnings after tax | Total                    |
|--------------------------------------------|-----------------------------|----------------------|-----------------------------|----------------------------------|--------------------------|
| <b>Balance as at 01/01/2026</b>            | <b>324,580,840,000</b>      | <b>9,442,260,000</b> | <b>94,353,394,407</b>       | <b>771,818,386,400</b>           | <b>1,200,194,880,807</b> |
| Capital increase during the period         | 81,144,750,000              | -                    | -                           | -                                | 81,144,750,000           |
| Profit for the period                      | -                           | -                    | -                           | 113,590,057,971                  | 113,590,057,971          |
| Appropriation to development investment fi | -                           | -                    | -                           | -                                | -                        |
| Appropriation to reward and welfare fund   | -                           | -                    | -                           | (14,172,092,666)                 | (14,172,092,666)         |
| Stock dividends distributed                | -                           | -                    | -                           | (81,144,750,000)                 | (81,144,750,000)         |
| Cash dividends distributed                 | -                           | -                    | -                           | (32,458,047,200)                 | (32,458,047,200)         |
| Appropriation to the Management Board bo   | -                           | -                    | -                           | (17,597,437,788)                 | (17,597,437,788)         |
| Bonus to the Board of Directors and Superv | -                           | -                    | -                           | (88,000,000)                     | (88,000,000)             |
| <b>Balance as at 30/06/2026</b>            | <b>405,725,590,000</b>      | <b>9,442,260,000</b> | <b>94,353,394,407</b>       | <b>739,948,116,717</b>           | <b>1,249,469,361,124</b> |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

***b. Details of owners' contributed capital***

|                                                 | <b>30/06/2026</b>      | <b>Tỷ lệ</b> | <b>01/01/2026</b>      | <b>Tỷ lệ</b> |
|-------------------------------------------------|------------------------|--------------|------------------------|--------------|
|                                                 | VND                    | %            | VND                    | %            |
| CPC1 Central Pharmaceutical Joint Stock Company | 66,666,650,000         | 16.43        | 53,333,320,000         | 16.43        |
| Ms. Le Thi Kim Anh                              | 69,749,970,000         | 17.19        | 55,799,980,000         | 17.19        |
| Mr. Nguyen Tien Lung                            | 33,333,320,000         | 8.22         | 26,666,660,000         | 8.22         |
| Mr. Le Nam Thang                                | 42,518,850,000         | 10.48        | 33,015,080,000         | 10.17        |
| Mr. Nguyen Thanh Binh                           | 78,216,620,000         | 19.28        | 62,573,300,000         | 19.28        |
| Ms. Phung Thanh Huong                           | 41,599,970,000         | 10.25        | 33,279,980,000         | 10.25        |
| Other shareholders                              | 73,640,210,000         | 18.15        | 59,912,520,000         | 18.46        |
|                                                 | <b>405,725,590,000</b> | <b>100</b>   | <b>324,580,840,000</b> | <b>100</b>   |

***c. Shares***

|                                          | <b>30/06/2026</b> | <b>01/01/2026</b> |
|------------------------------------------|-------------------|-------------------|
| Number of shares registered for issuance | 40,572,559        | 32,458,084        |
| Number of shares issued                  | 40,572,559        | 32,458,084        |
| - Ordinary shares                        | 40,572,559        | 32,458,084        |
| - Preference shares                      | -                 | -                 |
| Number of shares outstanding             | 40,572,559        | 32,458,084        |
| - Ordinary shares                        | 40,572,559        | 32,458,084        |
| - Preference shares                      | -                 | -                 |
| - Par value per share: VND 10,000        |                   |                   |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**VI. ADDITIONAL INFORMATION FOR ITEMS PRESENTED ON THE INCOME STATEMENT**

**1. REVENUES FROM SALES OF GOODS AND RENDERING OF SERVICES**

|                                                     | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|-----------------------------------------------------|-------------------------------------------|-------------------------------------------|
| Revenue from sale of merchandise and finished goods | 879,561,275,500                           | 725,726,908,588                           |
| Revenue from rendering of services                  | 53,063,788                                | 124,107,950                               |
| <b>Cộng</b>                                         | <b>879,614,339,288</b>                    | <b>725,851,016,538</b>                    |

**2. REVENUE DEDUCTIONS**

|                                | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|--------------------------------|-------------------------------------------|-------------------------------------------|
| Sales returns                  | 3,748,328,561                             | 1,526,997,150                             |
| Sales allowances and discounts | 601,255,591                               | 905,356,180                               |
| <b>Cộng</b>                    | <b>4,349,584,152</b>                      | <b>2,432,353,330</b>                      |

**3. COST OF GOODS SOLD AND SERVICES RENDERED**

|                                     | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|-------------------------------------|-------------------------------------------|-------------------------------------------|
| Cost of goods and services provided | 458,785,934,020                           | 339,811,110,237                           |
| <b>Cộng</b>                         | <b>458,785,934,020</b>                    | <b>339,811,110,237</b>                    |

**4. FINANCIAL INCOME**

|                                         | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|-----------------------------------------|-------------------------------------------|-------------------------------------------|
| Interest income from deposits and loans | 1,486,521,898                             | 349,851,266                               |
| Foreign exchange gains                  | 803,794,649                               | 254,454,374                               |
| Other financial income                  | 61,000,000                                | -                                         |
| <b>Cộng</b>                             | <b>2,351,316,547</b>                      | <b>604,305,640</b>                        |

**5. FINANCIAL EXPENSES**

|                          | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|--------------------------|-------------------------------------------|-------------------------------------------|
| Interest expense         | 2,244,270,926                             | 2,132,292,098                             |
| Foreign exchange losses  | 186,329,728                               | 824,988,321                               |
| Other financial expenses | 251,983,303                               | -                                         |
| <b>Total</b>             | <b>2,682,583,957</b>                      | <b>2,957,280,419</b>                      |

**6. OTHER INCOME**

|              | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|--------------|-------------------------------------------|-------------------------------------------|
| Other income | 731,121,949                               | 242,006,213                               |
| <b>Cộng</b>  | <b>731,121,949</b>                        | <b>242,006,213</b>                        |

**NOTES TO FINANCIAL STATEMENTS (CONTINUED)**

*These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements*

**7. OTHER EXPENSES**

|                                              | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|----------------------------------------------|-------------------------------------------|-------------------------------------------|
| Non-deductible depreciation expense          | 60,055,777                                | 67,704,060                                |
| Corporate income tax payable for prior years | -                                         | 15,808,476,662                            |
| Other expenses                               | 221,654,836                               | 5,478,305,207                             |
| <b>Total</b>                                 | <b>281,710,613</b>                        | <b>21,354,485,929</b>                     |

**8. SELLING EXPENSES**

|                                                  | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|--------------------------------------------------|-------------------------------------------|-------------------------------------------|
| Staff costs                                      | 143,070,118,807                           | 128,812,371,992                           |
| Tools and supplies expense                       | 5,017,201,340                             | 3,429,557,247                             |
| Depreciation of fixed assets                     | 4,241,048,555                             | 2,511,709,887                             |
| Promotion and product/goods sponsorship expenses | 6,795,809,832                             | 2,971,183,172                             |
| Outsourced services expense                      | 68,741,588,468                            | 47,186,857,829                            |
| Other expenses                                   | 39,417,791,049                            | 15,645,980,553                            |
| <b>Total</b>                                     | <b>267,283,558,051</b>                    | <b>200,557,660,680</b>                    |

**9. GENERAL AND ADMINISTRATION EXPENSES**

|                                            | From January 1, 2026,<br>to June 30, 2026 | From January 1, 2025,<br>to June 30, 2025 |
|--------------------------------------------|-------------------------------------------|-------------------------------------------|
| Staff costs                                | 8,820,079,868                             | 8,712,674,504                             |
| Office supplies expense                    | 727,897,689                               | 540,223,028                               |
| Depreciation of fixed assets               | 1,686,326,112                             | 1,324,129,136                             |
| Taxes, fees and charges                    | 929,505,636                               | 1,138,754,734                             |
| Provision for/(reversal of) doubtful debts | 185,259,467                               | -                                         |
| Outsourced services expense                | 7,262,054,982                             | 5,369,284,149                             |
| Other expenses                             | 2,510,222,082                             | 1,913,536,099                             |
| <b>Total</b>                               | <b>22,121,345,836</b>                     | <b>18,998,601,650</b>                     |

*Ha Noi, 20 July 2026*

**Preparer**



**Nguyen Thi Xuan Hoan**

**Chief Accountant**



**Dang Thi Thu Thuy**

**Chairman of the Board of Directors**



**Le Nam Thang**



**HA NOI CPC1 PHARMACEUTICAL  
JOINT STOCK COMPANY**

**SOCIALIST REPUBLIC OF VIETNAM**  
**Independence – Freedom - Happiness**

No. 300/2026/CV-CPC1HN

*Ha Noi, July 20, 2026*

Ref: Explanation regarding the profit after tax in the Income  
Statement of quarter 2/2026 changing by 10% or more  
compared to quarter 2/2025

To: - State Securities Commission of Vietnam  
- Hanoi Stock Exchange

Pursuant to the Ministry of Finance's Circular 96/2020/TT-BTC, dated 16 November 2020, of guidance on information disclosure on the stock market.

Based on the Income Statements in the Financial Statements for Q2/2026 and Q2/2025, Hanoi CPC1 Pharmaceutical Joint Stock Company hereby provides the following explanation for the Q2/2026 Financial Statements:

+ Profit after tax in Q2/2026: VND 58.226 billion

+ Profit after tax in Q2/2025: VND 76.092 billion

**The after-tax corporate income profit for Q2/2026 decreased by VND 17.86 billion compared with Q2/2025, a decrease of more than 10% year-on-year**

• **Main reasons for this decrease:**

- Cost of goods sold in Q2/2026 increased by 31.6%, equivalent to an increase of VND 57.60 billion compared with Q2/2025, due to rising prices of raw materials and input goods amid market fluctuations.

- Selling expenses in Q2/2026 increased by 35.4%, equivalent to an increase of VND 38.52 billion compared with Q2/2025, due to higher payroll costs, expansion of sales and business channels, and the Company's ongoing investment in major repairs and construction of new production facilities to meet business needs, which increased payable expenses

In addition, net revenue in Q2/2026 grew by only 17.5%, equivalent to an increase of VND 68.94 billion compared with Q2/2025, a lower rate of growth than that of cost of goods sold and selling expenses.

**Taken together, these factors resulted in a decrease of VND 17.86 billion in after-tax profit for Q2/2026 compared with Q2/2025**

The above is the explanation of Hanoi CPC1 Pharmaceutical Joint Stock Company regarding the change of 10% or more in profit after tax in the Income Statement for Q2/2026 compared to Q2/2025.

Sincerely,

**Recipients:**

- As addressed;
- Filing: Office Copy

**CHAIRMAN OF THE BOARD OF DIRECTORS**



**Lê Nam Thắng**